Picture of Anebulo Pharmaceuticals logo

ANEB Anebulo Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m-18.93%
3m-12.29%
6m-36.84%
1yr-31.77%
Volume Change (%)
10d/3m-57.65%
Price vs... (%)
52w High-38.27%
50d MA-3.12%
200d MA-1.48%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-164.37%
Return on Equity-95.37%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Anebulo Pharmaceuticals EPS forecast chart

Profile Summary

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system.

Directors

    Last Annual
    June 30th, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    April 23rd, 2020
    Public Since
    May 7th, 2021
    No. of Shareholders
    1
    No. of Employees
    2
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    25,933,217

    ANEB Share Price Performance

    Upcoming Events for ANEB

    Q3 2024 Anebulo Pharmaceuticals Inc Earnings Release

    Q4 2024 Anebulo Pharmaceuticals Inc Earnings Release

    Similar to ANEB

    Picture of 180 Life Sciences logo

    180 Life Sciences

    us flag iconNASDAQ Capital Market

    Picture of Abeona Therapeutics logo

    Abeona Therapeutics

    us flag iconNASDAQ Capital Market

    Picture of ABVC Biopharma logo

    ABVC Biopharma

    us flag iconNASDAQ Capital Market

    Picture of Acesis Holdings logo

    Acesis Holdings

    us flag iconNASDAQ Capital Market

    Picture of Achieve Life Sciences logo

    Achieve Life Sciences

    us flag iconNASDAQ Capital Market

    FAQ